Dupixent (dupilumab) is a brand-name injection that’s ... Dupixent and several other biologic medications approved as add-on medications for treating asthma are recognized as treatment options ...

With the notable exception of the anti-IgE monoclonal antibody omalizumab, early clinical trials with cytokine-targeted biologics in patients with asthma were, for the most part, disappointing ...

The FDA has approved AstraZeneca’s asthma injection, benralizumab ... Analyst GlobalData forecasts that anti-eosinophilic biologic therapies will make up 19% of US COPD market sales in 2025 ...

Side effects of biologic drugs may include: respiratory infections headaches flu-like symptoms swelling, itching, or a rash at the injection site urinary tract infection Two types of biologic ...

Enable Injections is a combination product company that is synonymous with large-volume wearable injectors. When biopharma companies want to make their biologics more convenient for patients ...

T2-high asthma, which is characterised by allergic inflammation and elevated eosinophil levels, has seen significant advances in treatment and disease management with the advent of biological ...

including high-concentration and high-viscosity biologics (Fig.1). The device also allows data related to drug, dosage, injection frequency and other relevant parameters to be collected ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...